Načítá se...
Second line chemotherapy and visceral metastases are associated with poor survival in patients with mCRPC receiving (177)Lu-PSMA-617
The purpose of this study was to identify previous treatments and biomarker profile features that prognosticate overall survival (OS) in patients with mCRPC receiving (177)Lu-PSMA-617. Methods: 109 mCRPC patients treated with a median of 3 cycles of (177)Lu-PSMA-617 were included. Data were analyzed...
Uloženo v:
| Vydáno v: | Theranostics |
|---|---|
| Hlavní autoři: | , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Ivyspring International Publisher
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6691377/ https://ncbi.nlm.nih.gov/pubmed/31410185 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/thno.35759 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|